CA2867188A1 - Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use - Google Patents

Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use Download PDF

Info

Publication number
CA2867188A1
CA2867188A1 CA2867188A CA2867188A CA2867188A1 CA 2867188 A1 CA2867188 A1 CA 2867188A1 CA 2867188 A CA2867188 A CA 2867188A CA 2867188 A CA2867188 A CA 2867188A CA 2867188 A1 CA2867188 A1 CA 2867188A1
Authority
CA
Canada
Prior art keywords
domain
polypeptide
protein
complex
surf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2867188A
Other languages
English (en)
French (fr)
Inventor
Erik M. Vogan
Alex Franzusoff
John Edwards
Ann DEWITT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PERMEON BIOLOGICS Inc
Original Assignee
PERMEON BIOLOGICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PERMEON BIOLOGICS Inc filed Critical PERMEON BIOLOGICS Inc
Publication of CA2867188A1 publication Critical patent/CA2867188A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2867188A 2012-03-15 2013-03-15 Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use Abandoned CA2867188A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611493P 2012-03-15 2012-03-15
US61/611,493 2012-03-15
PCT/US2013/032686 WO2013138795A1 (en) 2012-03-15 2013-03-15 Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Publications (1)

Publication Number Publication Date
CA2867188A1 true CA2867188A1 (en) 2013-09-19

Family

ID=49161881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867188A Abandoned CA2867188A1 (en) 2012-03-15 2013-03-15 Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Country Status (6)

Country Link
US (1) US20150266939A1 (https=)
EP (1) EP2825561A4 (https=)
JP (1) JP2015512246A (https=)
AU (1) AU2013231851A1 (https=)
CA (1) CA2867188A1 (https=)
WO (1) WO2013138795A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066132A3 (en) * 2015-10-13 2017-05-26 Formurex, Inc. Synthetic antibody mimic peptides

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2928915A4 (en) * 2012-12-07 2016-07-27 Permeon Biolog Inc FGF-10 COMPLEX
WO2015069587A2 (en) * 2013-11-06 2015-05-14 Merck Sharp & Dohme Corp. Peptide containing conjugates for dual molecular delivery of oligonucleotides
SG10201811729PA (en) * 2013-12-12 2019-02-27 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
JP2017504325A (ja) * 2014-01-14 2017-02-09 インテグレイテッド バイオセラピューティクス，インコーポレイテッド バクテリオシンの細胞壁ターゲティングドメインを用いた細菌感染部位への免疫学的機能のターゲティング方法
EP3104873B1 (en) 2014-02-13 2019-09-04 Technische Universität München Fgf-8 for use in treating diseases or disorders of energy homeostasis
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
IL313511A (en) 2014-11-12 2024-08-01 Seagen Inc Compounds acting on glycans and methods of using them
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2016172187A1 (en) * 2015-04-20 2016-10-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and compositions related to kras inhibitors
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
US10604558B2 (en) * 2016-01-05 2020-03-31 Colorado State University Research Foundation Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
US11318139B2 (en) 2016-01-26 2022-05-03 Dana-Farber Cancer Institute, Inc. Methods for treating brain metastases using combinations of anti-P13K and anti-mTOR agents
CN105837665B (zh) * 2016-05-16 2019-04-30 江苏大学 特异性抑制hb-egf促肿瘤细胞迁移浸润的多肽
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
US11524988B2 (en) 2016-09-19 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3556766B1 (en) * 2016-12-16 2024-07-31 Avixgen Inc. Use of a cell membrane penetrating peptide and intracellular delivery carrier including the same
WO2018111051A1 (ko) * 2016-12-16 2018-06-21 (주)에빅스젠 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
WO2018156735A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
KR101933217B1 (ko) * 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
JP7374502B2 (ja) 2018-05-03 2023-11-07 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Ｏｃａ－ｂペプチドコンジュゲート及び処置方法
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
WO2019240431A1 (ko) * 2018-06-14 2019-12-19 (주) 에빅스젠 세포 투과 펩티드 및 rpe65의 융합 단백질을 포함하는 레버 선천성 흑암시 치료용 약학적 조성물
EP3808762A4 (en) 2018-06-14 2022-03-30 Avixgen Inc. FUSION PROTEIN BOUND TO CELL PERMEABLE PEPTIDE AND COMPOSITION CONTAINING FUSION PROTEIN OR CELL PERMEABLE PEPTIDE AND EPITHELIAL CELL GROWTH FACTOR AS ACTIVE INGREDIENTS
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN115667302A (zh) 2020-02-06 2023-01-31 亚洲大学校产学协力团 将抗原衍生t细胞抗原表位或含所述表位的肽呈递到细胞表面的融合抗体及含所述融合抗体的组合物
CA3176046A1 (en) * 2020-05-04 2021-11-11 Michael C. BASSIK Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression
US20230257429A1 (en) * 2020-07-13 2023-08-17 National University Of Singapore Peptide adjuvant for its therapeutic applications in viral and tumour vaccine development and cancer immunotherapy and autoimmune disease diagnosis and treatments
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases
CN117736338A (zh) * 2023-12-08 2024-03-22 温州医科大学 一种角质细胞生长因子-透皮肽融合蛋白及其制备与应用
EP4711380A1 (en) * 2024-09-16 2026-03-18 Fundació Institut Hospital del Mar d'Investigacions Mèdiques Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743422B1 (en) * 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU5440800A (en) * 1999-05-21 2000-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 10
EE200200531A (et) * 2002-09-17 2004-04-15 O� InBio Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
AU2010238346A1 (en) * 2009-04-14 2011-11-03 Trojan Technologies Ltd. Therapeutic Antennapedia-antibody molecules and methods of use thereof
JP2012525146A (ja) * 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
EP2928915A4 (en) * 2012-12-07 2016-07-27 Permeon Biolog Inc FGF-10 COMPLEX

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066132A3 (en) * 2015-10-13 2017-05-26 Formurex, Inc. Synthetic antibody mimic peptides
US9957325B2 (en) 2015-10-13 2018-05-01 Formurex, Inc. Synthetic antibody mimic peptides

Also Published As

Publication number Publication date
EP2825561A1 (en) 2015-01-21
EP2825561A4 (en) 2016-03-09
AU2013231851A1 (en) 2014-09-11
US20150266939A1 (en) 2015-09-24
WO2013138795A1 (en) 2013-09-19
JP2015512246A (ja) 2015-04-27

Similar Documents

Publication Publication Date Title
CA2867188A1 (en) Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use
US11560435B2 (en) MUC1* antibodies
US20160031985A1 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
CN105518028B (zh) 与dll4和vegf特异性结合的新型双靶向蛋白及其用途
CN112409483B (zh) 抗pd-l1纳米抗体
JP7482488B2 (ja) Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質
KR101602870B1 (ko) 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
DK2814842T3 (en) ANTIBODIES BINDING PEPTIDOGLYCAN RECOGNITION PROTEIN 1
CN103003306B (zh) 抗体
CN106459187A (zh) 用于抗葡萄球菌剂的吞噬细胞递送的组合物和方法
AU2005216126B2 (en) Binding peptidomimetics and uses of the same
GB2449354A (en) Anti-DLL4 binding protein
US20100297664A1 (en) Paratope and epitope of anti-mortalin antibody
WO2014043509A2 (en) Antigen binding molecule with terminal modifications
CN110049998A (zh) 针对程序性细胞死亡1(pd-1)的新抗体及其用途
US20140271640A1 (en) FGF-10 Complexes
US20150307576A1 (en) Fgf-10 complexes
CN113614103A (zh) 不直接向其附着的细胞传导信号的非天然nkg2d受体
CN113227127A (zh) 向胃肠系统递送酬载的btnl3/8导引构建体
CN116829584B (zh) 一种抗pd-1的单域抗体
US20240190934A1 (en) Engineered interleukin-10 and fusion proteins thereof
WO2024003555A1 (en) Chemokine-binding peptides
US20150030593A1 (en) Compositions of penetration-enhanced targeting proteins and methods of use
EP3613766B1 (en) Polypeptide improved in protein purity and affinity for antigen, conjugate thereof with antibody or antigen-binding fragment, and preparation method therefor
WO2004046187A2 (en) Antibodies for in vitro use

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180315